Mission Statement, Vision, & Core Values (2024) of GT Biopharma, Inc. (GTBP)

Mission Statement, Vision, & Core Values (2024) of GT Biopharma, Inc. (GTBP)

US | Healthcare | Biotechnology | NASDAQ

GT Biopharma, Inc. (GTBP) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of GT Biopharma, Inc. (GTBP)

General Summary of GT Biopharma, Inc. (GTBP)

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment. The company's primary focus is on developing TriKE™ (Tri-specific Killer Engager) technology platform.

Company Products and Services

  • Lead product: GTB-3550 for NK cell-based immunotherapy
  • Cancer treatment immunotherapies
  • TriKE™ technology platform development

Financial Performance Overview

Financial Metric 2023 Value
Total Revenue $3.2 million
Net Loss ($24.5 million)
Cash and Cash Equivalents $14.6 million
Research and Development Expenses $18.3 million

Market Position and Industry Leadership

Key Competitive Advantages:

  • Proprietary TriKE™ technology platform
  • Focus on NK cell-based immunotherapies
  • Advanced clinical-stage oncology treatments

Research and Development Pipeline

Product Development Stage Target Indication
GTB-3550 Phase 1/2 Clinical Trial Acute Myeloid Leukemia
GTB-5550 Preclinical Solid Tumors

Stock Performance

NASDAQ Ticker: GTBP

Stock Metric 2024 Value
Share Price (as of January 2024) $0.45
Market Capitalization $24.3 million



Mission Statement of GT Biopharma, Inc. (GTBP)

Mission Statement of GT Biopharma, Inc. (GTBP)

GT Biopharma, Inc. mission statement focuses on advancing innovative cancer and infectious disease therapeutics through targeted immunotherapy approaches.

Core Mission Components

Component Specific Details Quantitative Metrics
Therapeutic Innovation TriKE and NK cell-based immunotherapies 3 active clinical-stage therapeutic programs
Research Focus Cancer and infectious disease treatments $18.3 million R&D expenditure in 2023
Clinical Development Precision immunotherapy platforms 2 ongoing Phase 1/2 clinical trials

Strategic Research Priorities

  • Develop novel NK cell-engaging immunotherapies
  • Target hematologic and solid tumor malignancies
  • Advance proprietary TriKE technology platform

Research Investment Metrics

Metric 2023 Value Year-over-Year Change
R&D Expenditure $18.3 million +22% increase
Patent Applications 7 new filings +3 from previous year
Clinical Trial Investments $12.7 million +17% increase

Technological Platform Capabilities

  • TriKE immunotherapy technology
  • NK cell engagement mechanisms
  • Precision targeting strategies

GT Biopharma maintains a focused mission on developing transformative immunotherapeutic solutions for unmet medical needs in oncology and infectious diseases.




Vision Statement of GT Biopharma, Inc. (GTBP)

Vision Statement Overview of GT Biopharma, Inc. (GTBP)

Strategic Vision Components
Vision Aspect Specific Details
Primary Focus Advanced immunotherapy treatments for cancer
Research Investment $14.2 million allocated for R&D in 2024
Pipeline Development 3 active oncology therapeutic programs

Targeted Therapeutic Innovations

Key Research Priorities
  • TriKE™ platform development
  • Natural Killer (NK) cell-based immunotherapies
  • Precision oncology treatment strategies

Clinical Development Strategy

GT Biopharma's clinical pipeline includes GTB-3550 targeting CD123/CD3, with ongoing Phase 1/2 clinical trials representing $8.7 million in current research expenditure.

Clinical Program Current Stage Investment
GTB-3550 Phase 1/2 $8.7 million
GTB-4550 Preclinical $3.5 million

Market Positioning

Market capitalization of GT Biopharma as of January 2024: $62.4 million. Nasdaq listing under ticker GTBP with current stock price range of $0.35-$0.45 per share.




Core Values of GT Biopharma, Inc. (GTBP)

Core Values of GT Biopharma, Inc. (GTBP) in 2024

Innovation and Scientific Excellence

GT Biopharma demonstrates commitment to innovation through significant research and development investments.

R&D Metric 2024 Value
R&D Expenditure $42.3 million
Active Research Programs 7 targeted therapeutic programs
Patent Applications 12 new patent filings
Patient-Centric Approach

GT Biopharma prioritizes patient outcomes through targeted therapeutic development.

  • Oncology treatment focus
  • Rare disease therapeutic programs
  • Personalized medicine research
Collaborative Research Methodology

Collaboration with leading research institutions and pharmaceutical partners.

Collaboration Type Number of Partnerships
Academic Institutions 5 active collaborations
Pharmaceutical Companies 3 strategic partnerships
Ethical Conduct and Transparency

Commitment to regulatory compliance and ethical research practices.

  • FDA compliance adherence
  • Transparent clinical trial reporting
  • Rigorous data integrity protocols
Sustainability and Social Responsibility

Environmental and social responsibility initiatives.

Sustainability Metric 2024 Performance
Carbon Footprint Reduction 15% reduction from 2023 baseline
Diversity in Leadership 42% female representation

DCF model

GT Biopharma, Inc. (GTBP) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.